The Serie A Femminile team, AS Roma Women have announced a new sponsorship agreement with a multi-business insurance company, HDI Assicurazioni.
In line with its ongoing partnership with the men’s first team, HDI Assicurazioni has now demonstrated its dedication to the squad by signing on as a partner in the ‘Insurance’ category for the 2023–24 campaign with the female Italian Champions.
Following the selection of renowned and accomplished athlete Federica Pellegrini as a brand ambassador and testimonial, HDI Assicurazioni has also decided to collaborate with AS Roma Women. This demonstrates the business’s willingness to invest in the sports sector while dispelling gender stereotypes and advancing the ideals of fairness, tenacity, devotion, and hard work.
HDI has already made its debut on Giallorosse’s shorts in the Italian Super Cup final versus Juventus FC on January 7. The brand’s logo has also begun to be featured on advertising boards at the Stadio Tre Fontane and press conference backdrops.
Michael Wandell, Chief Commercial & Brand Officer of AS Roma, said, “We couldn’t be more excited to welcome another prestigious global partner to our Italian Champions. Together with HDI Assicurazioni, we are proud to reaffirm our commitment to Women’s football.”
CEO of HDI Assicurazioni, Roberto Mosca, commented, “We’re excited to announce this partnership with AS Roma Women, a team that embodies values of excellence, dedication, and determination. This collaboration reinforces our commitment to support women’s sport and promote equal opportunities in football. AS Roma Women are inspirations for millions of people and we’re proud to be by their side in this exciting adventure.”
HDI Assicurazioni has been in business for almost a century and is part of the Talanx Group, which operates in more than 175 countries worldwide. HDI’s history begins in Italy, and the corporation has a special connection to Rome, where its headquarters is situated.
Last month, the Italian giants also developed a partnership with the global multinational pharmaceutical entity, IBSA.